Pharmaceutical company Novo Nordisk, maker of blockbuster weight loss drug Wegovy, says its CEO is stepping down ...

Lars Fruergaard Jørgensen will step down after eight years helming the Danish drugmaker, shares of which have shed half their ...

NVO stock gains after reporting first-quarter 2025 results, mainly due to expectations of U.S. sales recovery of its popular ...

Novo Nordisk's stock has declined 55% from its ... which increased revenue by 67.0% year-over-year to DKK 18,424 million. And while Saxenda sales declined steeply, the growth was especially ...

"Many people with obesity suffer from co-morbidities," said Novo Nordisk's chief science officer Mads Krogsgaard Thomsen, in a statement. "Saxenda has the potential to help some of these people ...

Welcome to the Q1 2025 Novo Nordisk A/S Earnings Conference Call ... partly offset by declining Saxenda sales as the obesity care market is growing towards once-weekly treatments.

FRANKFURT, Germany (AP) — Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster ... also includes another Novo weight loss drug, Saxenda. They have soared in popularity due ...

Danish pharmaceutical company Novo Nordisk A/S, maker of blockbuster weight ... that also includes another Novo weight loss drug, Saxenda. They have soared in popularity due to the amount of ...

As the FDA halts the sale of Ozempic and Zepbound copycats, online clinics have begun offering liraglutide, an older GLP-1 ...